Ollin Biosciences (@OllinBio) header
Ollin Biosciences (@OllinBio) profile picture

Redefining what’s possible in ophthalmology

Austin, TX
Joined February 2025
Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)Photo by Ollin Biosciences (@OllinBio)
Today, Ollin Biosciences announced it has entered into a definitive agreement to be acquired by Johnson & Johnson. Learn more: ollin.bio/press-releases/oll…
1
1
3
458
In wet age-related macular degeneration (wAMD), abnormal blood vessels grow and leak beneath the retina, threatening central vision. Swipe to learn more about #wAMD, the ongoing unmet need and how we're working to advance treatment options with OLN324.
1
51
Patients facing vision-threatening diseases are our North Star. The Ollin team has helped develop many of the therapies that define modern medical care in the #retina space. That experience shapes everything. Get to know our leadership below & learn more: ollin.bio/#team-section
39
Join us and leading international faculty on October 2 at @EURETINA in Vienna for a symposium on next-gen Ang2/VEGF dual inhibition and a presentation of OLN324 data from our Phase 1b JADE study. Learn more: ollin.bio/press-releases/oll… Symposium Registration: rsvp.theworldsbest.events/_w…
2
128
#VisionLoss from vision-threatening diseases affects millions of people worldwide. At Ollin, we're "all in" on changing that. Our mission is simple: develop best-in-disease therapies for conditions such as #DME, #wAMD and #TED. Learn more: ollin.bio/
28
Meet Daniel Kim, Sr. Director of Operations, Translational Research & Development Sciences, at Ollin. He leads nonclinical development operations, working closely with colleagues, partners and vendors to turn complex efforts into meaningful progress for patients.
1
30
We’re excited to join the #retina community at @asrsdocs! On Thursday, two members of our SAB will present our head-to-head Phase 1b JADE data evaluating OLN324 versus faricimab (Vabysmo®): David Eichenbaum on wAMD, and Veeral Sheth on DME. ollin.bio/press-releases/oll…
127
Looking back at #CTS2026: Dr. Margaret Chang presented 20-week JADE trial data showing OLN324 achieved faster and greater retinal drying vs. faricimab in #DME, with 93% of patients needing no retreatment after week 12. Watch the interview: retinalphysician.com/issues/…
172
We are excited to announce the closing of our oversubscribed $330 million Series B financing to advance global Phase 3 development of OLN324 and continued advancement of OLN102 for vision-threatening diseases. Read the full announcement: ollin.bio/press-releases/oll…
1
1
5
1,133
#HealthyVisionMonth is a time to reflect on advancing care for people living with retinal diseases like wet AMD & DME. In our JADE study, OLN324 demonstrated durable control of disease, including sustained improvements in key anatomic outcomes. Learn more: ollin.bio/
22
New final 20-week JADE data in DME and wAMD, showing favorable durability for OLN324 vs. faricimab (Vabysmo®) and more durable PED control, supporting its potential as a first-line treatment option. We look forward to Phase 3 studies this year. ollin.bio/press-releases/oll…
1
39
#TED is a debilitating and potentially vision-threatening complication of Graves’ disease. OLN102 may offer patients improved treatment. We look forward to entering clinical development this year. ollin.bio/ #AutoimmuneAwarenessMonth
39
Our CEO joined The BioHub Podcast to discuss his journey from physician-scientist to #biotech founder, and how those experiences shape Ollin’s approach today as we advance next-gen #ophthalmology therapies for serious, vision-threatening diseases. open.spotify.com/episode/6K3…
28
2B+ people live with vision impairment or blindness worldwide, according to @WHO. This #LowVisionAwarenessMonth, we’re proud to be pushing #ophthalmology innovation forward with the goal of delivering meaningful therapies for patients facing vision-threatening diseases.
21